Xuxi Zhang

Supplementary Table S2 Key Data in Studies DR Condition Study Intervention Group Control Group Event No event Event No event New onset DR among patients with type 2 diabetes ABCD trail, 2002 38 60 42 59 Kumamoto, 1995 2 24 8 17 Tovi, 1998 0 5 2 7 Rachmani, R., 2002 6 47 17 38 PREDIMED study, MedDiet+EVOO, 2015 22 1260 32 1158 PREDIMED study, MedDiet+Nuts, 2015 20 1122 32 1158 VADT, 2016 52 76 62 73 California Medi ‐ Cal Study, 2005 5 43 10 24 UKPDS 69, 2004 63 108 40 36 Lifestyle intervention study, 2002 4 29 10 18 VA CSDM, 1996 8 19 5 20 Worsening DR among patients with type 2 diabetes ABCD trail, 2002 33 64 46 55 Kumamoto, 1995 5 21 11 14 Tovi, 1998 5 9 2 5 UKPDS 69, 2004 39 90 38 38 VADT, 2016 54 251 66 224 Lifestyle intervention study, 2002 0 12 3 11 VA CSDM, 1996 13 23 17 25 DR Progression among patients with type 2 diabetes * Steno study, 1999 19 54 33 43 Steno study 2, 2003 38 29 51 12 ACCORDION Eye Study, 2016 ‐ Glycemic control study 38 620 83 569 ACCORDION Eye Study, 2016 ‐ Blood pressure study 21 259 16 252 ACCORDION Eye Study, 2016 ‐ Lipid study 47 352 37 326 ACCORD Eye Study, 2010 ‐ Glycemic control study 104 1325 149 1278 ACCORD Eye Study, 2010 ‐ Blood pressure study 67 580 64 552 ACCORD Eye Study, 2010 ‐ Lipid study 52 754 80 707 ADVANCE, 2008 332 5201 349 5191 AdRem Study, 2009 88 542 99 512 * For studies failing to provide distinctive data for new onset and worsening DR, the term “DR Progression” was adopted to cover both new onset and worsening DR DR, diabetic retinopathy 190 Chapter 7